// App-Quantinova.ai

PB0656 : Comparability of bleeding outcomes by prophylactic FVIII replacement intensity: A post-hoc analysis of a non-interventional study of men with severe hemophilia A

Researchers

Presenter

  • C. Camp

Principal Investigators

  • C. Hawes

  • D. Hinds

  • S. Hawley

  • D. Reddy

  • E. Goodman

Medical Centers

  • BioMarin Europe Ltd, London, England, United Kingdom

  • BioMarin Pharmaceutical Inc., Novato, United States

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • BMN-270

  • FVIII

Outcome

  • N/A

Study Design

  • Non Interventional

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • BioMarin Pharmaceutical Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved